Most women diagnosed with breast cancer have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) disease. The standard of care for managing advanced HR+/HER2- breast cancer relies upon CDK4/6 inhibitors plus endocrine therapy—a combination that prolongs survival compared with endocrine therapy alone. Although the 3 CDK4/6 inhibitors approved by the FDA (abemaciclib, palbociclib, and ribociclib) have demonstrated comparable efficacy in patients with advanced HR+/HER2- breast cancer, there are important differences in their safety profiles, dosing, and specific indications—including the recent approval of abemaciclib as adjuvant therapy for select patients with early-stage breast cancer. In this activity, Jeremy Force, DO, discusses the recommended use of CDK4/6 inhibitors in clinical practice along with strategies for monitoring and managing adverse events, promoting adherence, and educating patients.
eNewsletter with interactive benchmarking and audio commentary
After completing this activity, participants should be better able to:
- Formulate treatment plans for the appropriate use CDK4/6 inhibitors for HR+/HER2- breast cancer
- Use recommended approaches to manage toxicities associated with CDK4/6 inhibitors
- Implement recommendations to improve adherence to treatment with CDK4/6 inhibitors
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP Course Advisor: Cynthia L. Teeple, APRN, MSN, ONP, White Plains Hospital, White Plains, New York
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until November 23, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Force: consulting fees: Exact Sciences, Guardant Health, Pfizer; consulting fees/contracted research: G1 Therapeutics.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: November 24, 2021
Expiration date: November 23, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 103921L